Speaking at an American Brain Coalition webinar on the topic of psychedelics last month, FDA Division of Psychiatry Director Tiffany Farchione said, with a smirk, that psychedelics programs are “keeping us very busy.” “It’s not just an interest from the public,” she added, “it’s an interest from academia, from commercial drug sponsors as well.” “It is fully a third of my workload at this…
